UE2343, also known as Xanamem, is primarily investigated for its potential therapeutic applications in neurological disorders. It functions as an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is involved in the regulation of cortisol levels in the brain. By reducing cortisol activity, Xanamem is being explored as a treatment for conditions such as Alzheimer's disease, where elevated cortisol levels are associated with cognitive decline. Early clinical trials have focused on its ability to improve memory and cognitive function in patients with mild cognitive impairment or early-stage Alzheimer's. Additionally, its neuroprotective properties are being studied to assess its broader potential in managing stress-related cognitive impairments and other neurodegenerative diseases.